IVVDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Invivyd, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.61−0.01 (-1.39%)
Close on Oct 19, 2026
- Market cap
- $195.47M
- P/E (TTM)
- –
- Dividend yield
- –
Invivyd statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Biological Products, (No Diagnostic Substances) companies for comparison
Valuation
| Measure | Invivyd | Industry median |
|---|---|---|
| Market Cap | $179.80M | $164.85M |
| Enterprise Value | $19.72M | $87.06M |
| PS Ratio | 3.08 | 3.60 |
| PB Ratio | 0.99 | 2.03 |
| P/TBV Ratio | 0.99 | 2.31 |
Enterprise value
| Measure | Invivyd | Industry median |
|---|---|---|
| EV / Sales | 0.34 | 2.43 |
Income (trailing twelve months)
| Measure | Invivyd | Industry median |
|---|---|---|
| Revenue | $58.37M | $57.94M |
| Operating Income | -$112.53M | -$21.44M |
| Net Income | -$107.33M | -$22.46M |
| EBITDA | -$112.53M | -$16.91M |
| EPS (Diluted) | -$0.37 | -$0.83 |
Margins
| Measure | Invivyd | Industry median |
|---|---|---|
| Operating Margin | -192.8% | -44.5% |
| Profit Margin | -183.9% | -39.2% |
| EBITDA Margin | -192.8% | -31.3% |
| FCF Margin | -187.9% | -8.85% |
Returns
| Measure | Invivyd | Industry median |
|---|---|---|
| Return on Equity (ROE) | -95.9% | -53.1% |
| Return on Assets (ROA) | -69.7% | -41.0% |
| Return on Invested Capital (ROIC) | -615.6% | -32.0% |
| Return on Capital Employed (ROCE) | -59.9% | -37.8% |
Growth
| Measure | Invivyd | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 26.3% | 6.01% |
Balance sheet
| Measure | Invivyd | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $160.08M | $62.42M |
| Net Cash (Debt) | $160.08M | $15.68M |
| Net Cash Per Share | $0.54 | $0.66 |
| Equity (Book Value) | $181.08M | $48.79M |
| Book Value Per Share | $0.61 | $1.36 |
| Tangible Book Value | $181.08M | $23.06M |
| Working Capital | $151.08M | $75.77M |
Financial position
| Measure | Invivyd | Industry median |
|---|---|---|
| Current Ratio | 5.87 | 3.30 |
| Quick Ratio | 5.52 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Invivyd | Industry median |
|---|---|---|
| Operating Cash Flow | -$108.42M | -$12.35M |
| Capital Expenditures | -$1.24M | -$1.06M |
| Free Cash Flow | -$109.66M | -$20.28M |
| FCF Per Share | -$0.37 | -$0.42 |
Efficiency
| Measure | Invivyd | Industry median |
|---|---|---|
| Asset Turnover | 0.38 | 0.38 |
| Revenue Per Employee | $478.40K | $398.96K |
| Profits Per Employee | -$879.78K | -$703.34K |
| Employee Count | 122 | 74 |
Dividends and yields
| Measure | Invivyd | Industry median |
|---|---|---|
| Earnings Yield | -59.7% | -22.7% |
| FCF Yield | -61.0% | -9.07% |
| Buyback Yield | -0.22% | -0.73% |
| Shareholder Yield | -0.22% | 0.00% |
Shares
| Measure | Invivyd | Industry median |
|---|---|---|
| Shares Outstanding | 294,759,000 | 58,179,650 |
| Shares Change (YoY) | 125.1% | 11.1% |
| Shares Change (QoQ) | 4.23% | 0.54% |
| Float | 245,668,000 | 49,173,100 |
| Shares Held by Insiders | 16.7% | 11.6% |
| Shares Held by Institutions | 79.0% | 59.4% |
Taxes
| Measure | Invivyd | Industry median |
|---|---|---|
| Income Tax | $0 | $91.50K |
Scores
| Measure | Invivyd | Industry median |
|---|---|---|
| Altman Z-Score | -4.40 | -0.24 |
| Piotroski F-Score | 5 | 4 |
Calculated by StockData from Invivyd's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.